Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

39.14 +1.95 (+5.24%)
Delayed Quote Updated: 11:04 AM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review ↗
Xenon Pharmaceuticals (NASDAQ:XENE) said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program... 
Via MarketBeat
Triple Witching Whipsaws Wall Street While Crypto Stocks Steal the Show ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Xenon Pharmaceuticals (NASDAQ:XENE) Presents High-Quality Technical Breakout Setup ↗
Via Chartmill
Xenon Pharmaceuticals (NASDAQ:XENE) Reports Mixed Q1 Results as Azetukalner Nears FDA Submission ↗
Via Chartmill
XENON PHARMACEUTICALS INC (NASDAQ:XENE) Breakout Setup Combines 9/10 Technical Strength with 9/10 Consolidation Quality ↗
Via Chartmill
XENON PHARMACEUTICALS INC (NASDAQ:XENE) Reports Q4 and Full-Year 2025 Results, Focus Remains on Upcoming Phase 3 Data for Azetukalner ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript ↗
Azetukalner advances toward FDA submission as pain pipeline matures. 
Via The Motley Fool
Topics Earnings
News headline image
Xenon Pharmaceuticals Q2 Earnings Call Highlights ↗
10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara Bio. Excluding non-recurring settlement revenue in... 
Via MarketBeat
Topics Earnings
News headline image
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions. 
Via The Motley Fool
News headline image
Xenon Pharmaceuticals Q1 Earnings Call Highlights ↗
Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational... 
Via MarketBeat
Topics Earnings
News headline image
Xenon (XENE) Q1 2026 Earnings Transcript ↗
Xenon (XENE) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know ↗
This clinical-stage biotech advancing neurological therapies reported a notable insider sale as it progresses its drug pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗
This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗
This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗
Praxis Precision Medicines focuses on clinical-stage therapies for central nervous system disorders, targeting unmet needs in neurology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)
Date: March 12, 2026Sector: Biotechnology / NeurologyMarket Cap: ~$4.8 Billion Introduction On March 9, 2026, the neurology sector of the biotechnology market witnessed a seismic shift. Xenon... 
Via Finterra
Topics ETFs Intellectual Property
News headline image
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’ ↗
Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo. 
Via Stocktwits
Top stock movements in today's session. ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs. 
Via The Motley Fool
News headline image
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.